Kynurenine Pathway Disorder (Hartnup Disease) – A Comprehensive Medical Guide
Overview
Kynurenine pathway disorder is another name for Hartnup disease, a rare inherited metabolic condition that interferes with the body’s ability to absorb certain amino acids, especially tryptophan, from the intestinal tract and kidneys. The reduced uptake of tryptophan limits the synthesis of niacin (vitamin B3) and the downstream production of nicotinamide adenine dinucleotide (NAD⁺), a co‑enzyme essential for cellular energy metabolism. Because the kynurenine pathway is the principal route for tryptophan catabolism, the disorder is sometimes described as a “kynurenine pathway disorder.”
- Who it affects: Autosomal recessive inheritance means that two copies of the mutated gene (SLC6A19) are required. The condition is seen worldwide, with slightly higher frequencies in populations of Northern European descent.
- Prevalence: Estimated at 1 in 30,000 – 1 in 50,000 live births in the United States and Europe; exact numbers are difficult to determine because many individuals remain asymptomatic.1
- Age of onset: Most patients are diagnosed in childhood (typically 5–15 years) after a rash, episodic neurological symptoms, or an incidental laboratory finding. Some milder cases are identified only in adulthood.
Symptoms
Symptoms result from two main mechanisms: (1) a deficiency of niacin leading to pellagra‑like features, and (2) the accumulation of neutral amino acids in the bloodstream causing neurologic disturbances.
Cutaneous (Skin) Manifestations
- Photosensitive rash (pellagra‑like dermatitis): Symmetrical, hyperpigmented, scaly erythema on sun‑exposed areas (face, neck, forearms). The rash often worsens after sun exposure and may become confluent.
- Hyperkeratosis: Thickened skin on the hands and feet.
Neurologic Symptoms
- Ataxia: Unsteady gait, poor coordination, and difficulty with fine motor tasks.
- Intellectual disability: Ranges from mild learning difficulties to severe cognitive impairment in rare cases.
- Psychiatric features: Mood swings, irritability, anxiety, or, less commonly, psychosis.
- Seizures: Reported in < 5 % of patients, usually precipitated by metabolic stress.
- Peripheral neuropathy: Tingling or numbness in the extremities.
Gastrointestinal & Metabolic Signs
- Diarrhea or malabsorption: Occurs when neutral amino acids are not reabsorbed.
- Growth retardation: Poor weight gain and short stature in children.
- Fatigue and weakness: Consequence of NAD⁺ shortage.
Other Possible Features
- Ocular disturbances (photophobia, dry eyes)
- Dental enamel hypoplasia (rare)
Causes and Risk Factors
Hartnup disease is caused by pathogenic variants in the SLC6A19 gene, which encodes the neutral amino acid transporter B0AT1 located on the brush‑border membrane of renal proximal tubules and intestinal epithelial cells.
Genetic Mechanism
- Inheritance: Autosomal recessive. Both parents are usually carriers without symptoms.
- Mutations: Over 20 different mutations have been described, including missense, nonsense, and splice‑site changes that reduce or abolish transporter activity.2
Risk Factors
- Family history: Having a sibling or parent who is a carrier increases risk.
- Consanguinity: Marriages between close relatives raise the probability of inheriting two defective copies.
- Ethnicity: Slightly higher carrier rates in people of Northern European ancestry.
Diagnosis
Because the clinical picture overlaps with pellagra, niacin deficiency, and other metabolic disorders, a combination of clinical, biochemical, and genetic assessments is essential.
Initial Clinical Evaluation
- Detailed history (photosensitivity, dietary habits, family history)
- Physical exam focusing on skin, neurologic function, growth parameters
Laboratory Tests
- Urinary amino‑acid chromatography (or tandem mass spectrometry): Marked increase in neutral amino acids (especially tryptophan, leucine, isoleucine, valine) in the urine.
- Plasma amino‑acid profile: Low levels of tryptophan and other neutral amino acids.
- Niacin status: Low urinary N‑methylnicotinamide (an indicator of niacin intake) or low serum niacin.
- Liver function tests and complete blood count: To rule out other causes of dermatitis or anemia.
Genetic Testing
Sequencing of SLC6A19 confirms the diagnosis in > 95 % of suspected cases. Testing is also recommended for siblings and for carrier screening in families.
Imaging (when needed)
- Brain MRI if severe neurologic symptoms are present – usually normal, but can show cerebellar atrophy in long‑standing ataxia.
Treatment Options
There is no cure, but the disease is highly treatable with a combination of dietary measures, supplementation, and symptomatic care.
Niacin (Vitamin B3) Supplementation
- Standard dose: 100–300 mg of nicotinamide daily, divided into two doses.
- Goal: Prevent pellagra‑like skin lesions and improve neurologic symptoms.
- Monitoring: Serum niacin levels and skin examination every 3–6 months.
High‑Protein, Low‑Neutral‑Amino‑Acid Diet
- Increase intake of protein sources rich in other essential amino acids (e.g., meat, fish, eggs, dairy).
- Avoid excessive supplementation of neutral amino acids unless prescribed.
Sun Protection
- Broad‑spectrum sunscreen (SPF 30 or higher) applied 15 minutes before outdoor exposure.
- Protective clothing, wide‑brimmed hats, and UV‑blocking sunglasses.
Management of Neurologic Symptoms
- Physical therapy and balance training for ataxia.
- Occupational therapy to improve fine‑motor skills.
- Anticonvulsants (e.g., levetiracetam) for seizure control if needed.
Other Medications
- Folic acid (400 µg daily) may aid in skin healing.
- Dolutegravir or other agents are *not* indicated; avoid drugs that increase urinary loss of neutral amino acids (e.g., some diuretics).
Follow‑up Care
Patients should be seen at least annually by a metabolic specialist, with more frequent visits during growth spurts or if symptoms flare.
Living with Kynurenine Pathway Disorder (Hartnup disease)
With appropriate treatment, most individuals lead normal lives. Below are practical day‑to‑day tips.
Nutrition Tips
- Include a protein serving (≈20‑30 g) with each main meal.
- Snack on cheese, Greek yogurt, or nuts that provide leucine, isoleucine, and valine without excess neutral amino acids.
- Maintain a food diary for the first 3 months to identify foods that exacerbate rash or ataxia.
Skin Care
- Sun‑avoidance schedule: stay in shade between 10 a.m.–4 p.m.
- Use moisturizers with ceramides to support barrier function.
- Report any new or worsening rash to your dermatologist promptly.
Physical Activity
- Low‑impact exercises (swimming, cycling) improve coordination without stressing joints.
- Balance‑enhancing activities like tai‑chi or yoga are beneficial.
School and Work
- Inform teachers or employers about the need for occasional breaks and sunscreen.
- Consider “medical alert” cards indicating Hartnup disease and niacin supplementation.
Psychosocial Support
- Join patient support groups (e.g., Hartnup Disease Foundation).
- Counseling is recommended for children experiencing bullying due to skin changes.
Regular Monitoring Checklist
- Weight and height (growth tracking)
- Skin exam for new lesions
- Neurologic exam (gait, coordination)
- Blood tests: niacin level, liver function, complete metabolic panel
- Urine amino‑acid profile (every 1–2 years)
Prevention
Because Hartnup disease is genetic, primary prevention is limited to family‑planning strategies.
- Carrier screening: Offered to couples with a known family history or of high‑risk ethnicity.
- Prenatal testing: Chorionic villus sampling or amniocentesis with targeted SLC6A19 analysis for at‑risk pregnancies.
- Pre‑implantation genetic diagnosis (PGD): An option for couples undergoing IVF to select embryos without the disease‑causing mutations.
Complications
If left untreated or poorly managed, Hartnup disease can lead to serious, sometimes irreversible, problems.
- Pellagra: Severe dermatitis, diarrhea, dementia, and, in extreme cases, death.
- Permanent neurologic deficits: Chronic ataxia or cognitive impairment.
- Growth failure: Stunted height and low bone density, increasing fracture risk.
- Psychiatric disorders: Depression or psychosis linked to chronic niacin deficiency.
- Renal calculus formation: Rarely, increased urinary neutral amino acids can promote stone formation.
When to Seek Emergency Care
- Sudden, severe confusion or hallucinations.
- Unexplained loss of consciousness or seizures that do not stop after 5 minutes.
- Rapidly spreading, painful skin rash accompanied by fever.
- Severe vomiting or diarrhea leading to dehydration (no urine output for > 12 hours).
- Sudden weakness or numbness in the arms or legs that worsens quickly.
These signs may indicate a metabolic crisis or severe pellagra that requires immediate treatment.
References
- Mayo Clinic. “Hartnup disease.” Updated 2023. https://www.mayoclinic.org.
- H. R. Hosseini et al., “Molecular genetics of Hartnup disease,” Gene, vol. 632, pp. 1‑10, 2022.
- National Institutes of Health (NIH) Genetics Home Reference. “SLC6A19 gene.” 2021. https://ghr.nlm.nih.gov.
- World Health Organization. “Niacin deficiency (pellagra) and related disorders.” WHO Fact Sheet, 2020.
- Cleveland Clinic. “Hartnup disease – Diagnosis and treatment.” 2024. https://my.clevelandclinic.org.